ArticleAsian journal of neurosurgery2026
Clinical Effectiveness of a Blood-Based Biomarker in Patients with Mild Traumatic Brain Injury.
Article in Asian journal of neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Mild traumatic brain injury (mTBI) is among the most prevalent neurological conditions worldwide. Its diagnosis predominantly depends on computed tomography (CT) imaging, despite the majority of scans yielding negative results, leading to unnecessary resource utilization and avoidable radiation exposure. This study aims to investigate the potential of glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) as serum biomarkers for ruling out clinically significant intracranial injuries. Materials and Methods: This prospective cohort study enrolled adult patients (aged >18 years) presenting to the emergency department with nonpenetrating mTBI between October 2023 and October 2024. All participants underwent brain CT imaging and venous blood sampling for quantification of GFAP and UCH-L1. Diagnostic performance metrics, including sensitivity, specificity, positive predictive value, and negative predictive value, were calculated to assess biomarker accuracy in detecting intracranial abnormalities. Results: A total of 123 patients were enrolled, with a mean age of 70 years. The predominant mechanism of injury was a ground-level fall. The combined use of GFAP and UCH-L1 demonstrated excellent sensitivity (100%; 95% CI: 89.1-100%) and negative predictive value (100%; 95% CI: 76.8-100%) for detecting intracranial injury. However, specificity was low (15.4%; 95% CI: 8.7-24.5%), indicating limited ability to rule in pathology based on biomarker elevation alone. Conclusion: This study demonstrates the high sensitivity and negative predictive value of GFAP and UCH-L1 as a combined biomarker test for evaluating moderate- and high-risk mTBI. Patients with a negative biomarker result may safely forgo head CT, thereby reducing unnecessary radiation exposure and avoiding unwarranted CT utilization. Nevertheless, practical challenges remain before routine clinical adoption is feasible. Future cost analyses will be essential to determine the economic viability of these biomarkers, particularly in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.